Isofol Medical AB (OSTO:ISOFOL) Total Liabilities: kr21.08 Mil (As of Mar. 2026)


OSTO:ISOFOL Isofol Medical AB OSTO:ISOFOL
30 GF Score
Price kr0.81
! 2 Warning Signs
View Full Analysis

What is Isofol Medical AB Total Liabilities?

Isofol Medical AB OSTO:ISOFOL +5.88% 30 Total Liabilities is kr21.08 Mil as of Mar. 2026. GuruFocus rates OSTO:ISOFOL with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Isofol Medical AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr21.08 Mil.

Isofol Medical AB's quarterly Total Liabilities increased from Sep. 2025 (kr21.51 Mil) to Dec. 2025 (kr21.53 Mil) but then declined from Dec. 2025 (kr21.53 Mil) to Mar. 2026 (kr21.08 Mil).

Isofol Medical AB's annual Total Liabilities increased from Dec. 2023 (kr19.17 Mil) to Dec. 2024 (kr20.47 Mil) and increased from Dec. 2024 (kr20.47 Mil) to Dec. 2025 (kr21.53 Mil).


Isofol Medical AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Isofol Medical AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Isofol Medical AB Total Liabilities Chart

Isofol Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.13 51.39 19.17 20.47 21.53

Isofol Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.20 19.50 21.51 21.53 21.08
OSTO:ISOFOL
30GF Score
Isofol Medical AB OSTO:ISOFOL
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Isofol Medical AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Isofol Medical AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=129.397-107.872
=21.53

Isofol Medical AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=113.91-92.828
=21.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr21.08 Mil mean?
Isofol Medical AB (OSTO:ISOFOL) has a Total Liabilities of kr21.08 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Isofol Medical AB and its competitors.
Is Isofol Medical AB's Total Liabilities too high?
Isofol Medical AB's current Total Liabilities is kr21.08 Mil. Overall, Isofol Medical AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Isofol Medical AB's Total Liabilities compare to VRTX and REGN?
Isofol Medical AB's Total Liabilities of kr21.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Isofol Medical AB and its competitors. Isofol Medical AB's current Total Liabilities is kr21.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Isofol Medical AB stock overvalued right now?
Isofol Medical AB (OSTO:ISOFOL) has a current Total Liabilities of kr21.08 Mil. The current Total Liabilities is kr21.08 Mil. Isofol Medical AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Isofol Medical AB (OSTO:ISOFOL), the current Total Liabilities is kr21.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Isofol Medical AB Business Description

Address Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
30GF Score

Get the complete analysis for OSTO:ISOFOL

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.81
Price